NASDAQ:MNOV - MediciNova Stock Price, Price Target & More

$11.20 -0.36 (-3.11 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$11.20
Today's Range$11.17 - $11.85
52-Week Range$4.40 - $14.50
Volume178,686 shs
Average Volume340,651 shs
Market Capitalization$473.13 million
P/E Ratio-33.94
Dividend YieldN/A
Beta0.35

About MediciNova (NASDAQ:MNOV)

MediciNova logoMediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio9.83%
Quick Ratio9.83%

Price-To-Earnings

Trailing P/E Ratio-33.94
Forward P/E Ratio-29.47
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book10.47

Profitability

EPS (Most Recent Fiscal Year)($0.33)
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-32.09%
Return on Assets-28.09%

Miscellaneous

Employees9
Outstanding Shares40,930,000

How to Become a New Pot Stock Millionaire

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.

What price target have analysts set for MNOV?

1 brokerages have issued twelve-month target prices for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's stock price to reach $22.00 in the next year. View Analyst Ratings for MediciNova.

Who are some of MediciNova's key competitors?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)
  • Mr. Ryan J. Selhorn, CFO & Principal Accounting Officer (Age 36)
  • Mr. Masatsune Okajima, Head of Japanese Office and VP (Age 50)
  • Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)
  • Mr. Geoffrey G. O'Brien J.D., M.B.A., VP (Age 49)

Has MediciNova been receiving favorable news coverage?

Press coverage about MNOV stock has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MediciNova earned a news sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $11.20.

How big of a company is MediciNova?

MediciNova has a market capitalization of $473.13 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. MediciNova employs 9 workers across the globe.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (MNOV)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MediciNova (NASDAQ:MNOV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for MediciNova in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 96.43%. The high price target for MNOV is $22.00 and the low price target for MNOV is $22.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.00N/AN/AN/A
Price Target Upside: 96.43% upsideN/AN/AN/A

MediciNova (NASDAQ:MNOV) Consensus Price Target History

Price Target History for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ:MNOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018B. RileyInitiated CoverageBuy$22.00HighView Rating Details
4/18/2017Credit Suisse GroupInitiated CoverageOutperform -> OutperformHighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

MediciNova (NASDAQ:MNOV) Earnings History and Estimates Chart

Earnings by Quarter for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ:MNOV) Earnings Estimates

2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.12)($0.10)($0.11)
Q2 20182($0.11)($0.11)($0.11)
Q3 20182($0.12)($0.11)($0.12)
Q4 20182($0.14)($0.11)($0.13)

MediciNova (NASDAQ MNOV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/23/2017Q3 2017($0.09)($0.11)ViewN/AView Earnings Details
7/26/2017Q2 2017($0.10)($0.08)ViewN/AView Earnings Details
4/26/2017Q1 2017($0.10)($0.09)ViewN/AView Earnings Details
2/14/2017Q4 2016($0.04)ViewN/AView Earnings Details
10/25/2016Q3 2016($0.05)($0.08)ViewN/AView Earnings Details
7/26/2016Q2 2016($0.10)ViewN/AView Earnings Details
4/27/2016Q1 2016($0.08)($0.11)ViewN/AView Earnings Details
2/25/2016Q4 2015($0.09)ViewN/AView Earnings Details
10/29/2015Q3 2015($0.10)($0.06)ViewN/AView Earnings Details
7/30/2015Q2 2015($0.10)($0.09)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.10)($0.09)ViewN/AView Earnings Details
11/7/2013Q3 2013($0.10)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.14)$0.37 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.13)($0.14)$0.31 millionViewN/AView Earnings Details
3/28/2013Q4 2012($0.12)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.14)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.26)($0.14)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.28)($0.24)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.20)($0.22)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.28)($0.25)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.34)($0.31)ViewN/AView Earnings Details
5/17/2011Q1 2011($0.38)($0.45)ViewN/AView Earnings Details
3/31/2011Q4 2010($0.40)($0.40)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.42)($0.46)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.39)($0.35)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.41)($0.42)ViewN/AView Earnings Details
3/24/2010Q4 2009($0.40)($0.49)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.46)($0.40)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.39)($0.39)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.26)($0.41)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.12)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.66)($0.40)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.65)($0.33)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.70)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.92)($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MediciNova (NASDAQ:MNOV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MediciNova (NASDAQ MNOV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 18.79%
Insider Trading History for MediciNova (NASDAQ:MNOV)
Institutional Ownership by Quarter for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ MNOV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/21/2017Yoshio IshizakaDirectorBuy5,000$5.17$25,850.005,000View SEC Filing  
5/15/2017Yutaka KobayashiDirectorBuy1,000$5.60$5,600.0081,800View SEC Filing  
5/12/2017Yutaka KobayashiDirectorBuy24,000$5.62$134,880.0081,800View SEC Filing  
9/15/2016Yutaka KobayashiDirectorBuy11,800$6.44$75,992.0081,800View SEC Filing  
9/9/2016Yutaka KobayashiDirectorBuy10,000$6.67$66,700.0070,000View SEC Filing  
7/5/2016Geoffrey ObrienVPSell3,300$8.00$26,400.008,300View SEC Filing  
12/10/2014Yutaka KobayashiDirectorBuy12,000$3.54$42,480.00View SEC Filing  
11/26/2014Yutaka KobayashiDirectorBuy10,000$3.07$30,700.00View SEC Filing  
11/20/2014Yutaka KobayashiDirectorBuy13,000$3.19$41,470.00View SEC Filing  
11/19/2014Yoshio IshizakaDirectorBuy5,000$2.86$14,300.00View SEC Filing  
9/11/2014Yutaka KobayashiDirectorBuy10,000$2.95$29,500.00View SEC Filing  
9/3/2014Yutaka KobayashiDirectorBuy15,000$2.66$39,900.00View SEC Filing  
12/12/2013Tatsuo IzumiDirectorSell71,270$2.10$149,667.00View SEC Filing  
11/18/2013Tatsuo IzumiDirectorBuy1,270$2.21$2,806.70View SEC Filing  
5/21/2013Arlene MorrisDirectorSell8,800$3.28$28,864.00View SEC Filing  
5/13/2013Tatsuo IzumiDirectorBuy158,730$3.15$499,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MediciNova (NASDAQ MNOV) News Headlines

Source:
DateHeadline
3 Things In Biotech, April 16: Liver, Liver, And More Liver3 Things In Biotech, April 16: Liver, Liver, And More Liver
seekingalpha.com - April 17 at 10:00 AM
-$0.11 EPS Expected for MediciNova, Inc. (MNOV) This Quarter-$0.11 EPS Expected for MediciNova, Inc. (MNOV) This Quarter
www.americanbankingnews.com - April 16 at 3:12 PM
Zacks: MediciNova, Inc. (MNOV) Given $18.33 Average Target Price by BrokeragesZacks: MediciNova, Inc. (MNOV) Given $18.33 Average Target Price by Brokerages
www.americanbankingnews.com - April 15 at 3:11 AM
Medicinova (MNOV) Announces Presentation of Positive Results from Interim Analysis of Phase 2 Trial of MN-001 in NASH / NAFLDMedicinova (MNOV) Announces Presentation of Positive Results from Interim Analysis of Phase 2 Trial of MN-001 in NASH / NAFLD
www.streetinsider.com - April 14 at 9:51 AM
MediciNovas tipelukast shows treatment effect in mid-stage NASH/NAFLD study; shares up 8% premarketMediciNova's tipelukast shows treatment effect in mid-stage NASH/NAFLD study; shares up 8% premarket
seekingalpha.com - April 13 at 10:08 AM
MediciNovas MN-166 Has Significant Potential In Progressive MSMediciNova's MN-166 Has Significant Potential In Progressive MS
seekingalpha.com - April 13 at 10:08 AM
MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, FranceMediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France
finance.yahoo.com - April 13 at 10:08 AM
Your Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes Setback, BioLife Preliminary Q1 ResultsYour Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes' Setback, BioLife Preliminary Q1 Results
seekingalpha.com - April 3 at 4:20 PM
MediciNova (MNOV) Upgraded at ValuEngineMediciNova (MNOV) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM
Pre-Open Movers 04/02: (SLS) (MNOV) (CVLT) Higher; (ALKS) (SORL) (ITCI) Lower (more...)Pre-Open Movers 04/02: (SLS) (MNOV) (CVLT) Higher; (ALKS) (SORL) (ITCI) Lower (more...)
www.streetinsider.com - April 2 at 4:19 PM
Heres Why MediciNova Jumped as Much as 26.2% TodayHere's Why MediciNova Jumped as Much as 26.2% Today
www.msn.com - April 2 at 4:19 PM
Here's Why MediciNova Jumped as Much as 26.2% TodayHere's Why MediciNova Jumped as Much as 26.2% Today
finance.yahoo.com - April 2 at 4:19 PM
MediciNova Announces Phase 2 Trial of MN-001 (...MediciNova Announces Phase 2 Trial of MN-001 (...
www.benzinga.com - April 2 at 10:09 AM
MediciNovas MN-001 successful in mid-stage NASH studyMediciNova's MN-001 successful in mid-stage NASH study
seekingalpha.com - April 2 at 10:09 AM
 Analysts Anticipate MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per Share Analysts Anticipate MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - March 30 at 7:10 PM
MediciNova Flunks Mid-Stage Study, But Not All Is LostMediciNova Flunks Mid-Stage Study, But Not All Is Lost
seekingalpha.com - March 30 at 4:19 PM
MediciNova, Inc. Expected to Post Q1 2018 Earnings of ($0.10) Per Share (MNOV)MediciNova, Inc. Expected to Post Q1 2018 Earnings of ($0.10) Per Share (MNOV)
www.americanbankingnews.com - March 30 at 6:52 AM
MediciNova (MNOV) Upgraded by BidaskClub to BuyMediciNova (MNOV) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 29 at 4:10 PM
Zacks: Brokerages Set $18.33 Target Price for MediciNova, Inc. (MNOV)Zacks: Brokerages Set $18.33 Target Price for MediciNova, Inc. (MNOV)
www.americanbankingnews.com - March 29 at 1:26 PM
MediciNova teams up with Australian cancer center to evaluate MN-166 in chemotherapy-induced peripheral neuropathyMediciNova teams up with Australian cancer center to evaluate MN-166 in chemotherapy-induced peripheral neuropathy
seekingalpha.com - March 29 at 10:06 AM
Pre-Open Movers 03/29: (MOV) (MGEN) (PSDV) Higher; (ZSAN) (MNOV) (MCD) Lower (more...)Pre-Open Movers 03/29: (MOV) (MGEN) (PSDV) Higher; (ZSAN) (MNOV) (MCD) Lower (more...)
www.streetinsider.com - March 29 at 10:06 AM
B. Riley Initiates Coverage on MediciNova (MNOV)B. Riley Initiates Coverage on MediciNova (MNOV)
www.americanbankingnews.com - March 28 at 8:06 AM
MediciNova (MNOV) Raised to Buy at BidaskClubMediciNova (MNOV) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 1:58 PM
MediciNova (MNOV) Stock Rating Upgraded by ValuEngineMediciNova (MNOV) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 11:29 AM
MediciNova (MNOV) Stock Rating Upgraded by BidaskClubMediciNova (MNOV) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 25 at 9:51 AM
BidaskClub Lowers MediciNova (MNOV) to BuyBidaskClub Lowers MediciNova (MNOV) to Buy
www.americanbankingnews.com - March 22 at 12:54 AM
Critical Review: MediciNova (MNOV) & Regulus Therapeutics (RGLS)Critical Review: MediciNova (MNOV) & Regulus Therapeutics (RGLS)
www.americanbankingnews.com - March 19 at 1:55 AM
Analysts Expect MediciNova, Inc. (MNOV) to Announce ($0.09) Earnings Per ShareAnalysts Expect MediciNova, Inc. (MNOV) to Announce ($0.09) Earnings Per Share
www.americanbankingnews.com - March 13 at 9:26 PM
MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in TokyoMediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo
feeds.benzinga.com - March 12 at 8:34 PM
MediciNova (MNOV) & The Competition Financial SurveyMediciNova (MNOV) & The Competition Financial Survey
www.americanbankingnews.com - March 11 at 9:48 AM
Brokerages Expect MediciNova, Inc. (MNOV) to Announce ($0.09) EPSBrokerages Expect MediciNova, Inc. (MNOV) to Announce ($0.09) EPS
www.americanbankingnews.com - March 7 at 1:33 PM
MediciNova (MNOV) vs. Its Rivals Critical SurveyMediciNova (MNOV) vs. Its Rivals Critical Survey
www.americanbankingnews.com - March 4 at 9:28 AM
Financial Comparison: MediciNova (MNOV) & The CompetitionFinancial Comparison: MediciNova (MNOV) & The Competition
www.americanbankingnews.com - March 3 at 10:34 AM
Short Interest in MediciNova, Inc. (MNOV) Grows By 39.6%Short Interest in MediciNova, Inc. (MNOV) Grows By 39.6%
www.americanbankingnews.com - March 3 at 3:26 AM
MediciNova to Present at the Cowen Health Care Conference in BostonMediciNova to Present at the Cowen Health Care Conference in Boston
feeds.benzinga.com - February 25 at 6:51 PM
 Analysts Expect MediciNova, Inc. (MNOV) to Announce -$0.09 EPS Analysts Expect MediciNova, Inc. (MNOV) to Announce -$0.09 EPS
www.americanbankingnews.com - February 24 at 5:12 PM
Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet?Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet?
finance.yahoo.com - February 22 at 9:28 AM
Zacks Investment Research Comments on MediciNova, Inc.s Q1 2018 Earnings (MNOV)Zacks Investment Research Comments on MediciNova, Inc.'s Q1 2018 Earnings (MNOV)
www.americanbankingnews.com - February 19 at 2:04 AM
MNOV: Raises $40 Million in Underwritten Public OfferingMNOV: Raises $40 Million in Underwritten Public Offering
finance.yahoo.com - February 16 at 4:26 PM
Critical Analysis: MediciNova (MNOV) vs. Its PeersCritical Analysis: MediciNova (MNOV) vs. Its Peers
www.americanbankingnews.com - February 15 at 11:12 PM
MNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 StudyMNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 Study
finance.yahoo.com - February 9 at 9:04 AM
Here's Why MediciNova, Inc. Stock Is Sliding TodayHere's Why MediciNova, Inc. Stock Is Sliding Today
finance.yahoo.com - February 8 at 4:31 PM
Heres Why MediciNova, Inc. Stock Is Sliding TodayHere's Why MediciNova, Inc. Stock Is Sliding Today
www.fool.com - February 8 at 1:42 PM
Medicinova (MNOV) Prices 4.42M Common Share Offering at $9.05/ShMedicinova (MNOV) Prices 4.42M Common Share Offering at $9.05/Sh
www.streetinsider.com - February 8 at 9:03 AM
Zacks: Brokerages Expect MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per ShareZacks: Brokerages Expect MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 8 at 1:18 AM
ARRYs COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTDARRY's COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTD
www.nasdaq.com - February 7 at 9:03 AM
Active-Investors: Blog Exposure - MediciNovas MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b TrialActive-Investors: Blog Exposure - MediciNova's MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
www.finanznachrichten.de - February 5 at 8:59 AM
Blog Exposure - MediciNova’s MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b TrialBlog Exposure - MediciNova’s MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
finance.yahoo.com - February 5 at 8:59 AM
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, CaliforniaMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
finance.yahoo.com - January 31 at 9:12 AM
MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San DiegoMediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego
finance.yahoo.com - January 31 at 9:12 AM

SEC Filings

MediciNova (NASDAQ:MNOV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MediciNova (NASDAQ:MNOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MediciNova (NASDAQ MNOV) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.